No Detail Found!

Estimation of interleukin-6 level and atherogenic indices as predictors of severity of rheumatoid arthritis in Iraqi patients

Author(s)
Ghufran Abd Omran Abdulridha Department of Chemistry, Faculty of Science, University of Kufa, Najaf; Clinical Chemistry Branch, Faculty of Medicine Hammurabi, University of Babylon, Babylon, Iraq;
Mustafa Abdulkadhim Hussein Department of Chemistry, Faculty of Science, University of Kufa, Najaf, Iraq
Suhad Rasheed Majeed Department of Laboratory and Clinical Sciences, Faculty of Pharmacy, University of Kufa, Najaf, Iraq
Abstract
Background & Objective: Rheumatoid Arthritis (RA) is an inflammatory illness that causes joint degeneration and inflammation of the synovial membrane, leading to significant disability over time. Interleukin-6 (IL-6) is a widely distributed pro-inflammatory cytokine that has a variety of roles in several pathophysiologic systems, most notably in the RA development. The purpose of this study was to assess the blood levels of IL-6 and the severity and activity of RA in patients, and to assess the association of atherogenic indices with IL-6 as a predictor of severity in RA disease. Methodology: This study was a case control observational study involving 300 participants diagnosed with RA by the rheumatologists in accordance with American College of Rheumatologists (ACR)/ European League Against Rheumatism (EULAR) 2010 criteria. Serum levels of IL-6, CRP, RF and ACPA were measured by using ELISA technique. While, lipid profile was determined with spectrophotometry. Receiver operating curve (ROC) was used to study the opportunity of using atherogenic indices and IL-6 as diagnostic tools for RA. Results: The results indicated a higher IL-6 level in RA patients in comparison to the control group, e.g., 28.55 (18.7641.07) pg/mLvs 10.19 (6.11-12.50) pg/ml. High atherogenic index of plasma (AIP) risk > 0.24 in RA patients parameters (GDF-15, IL-6), the lipid profile parameters and atherogenic indices (TC, TG, VLDL-C, LDL-C, CRI-I, CRI-II, AIP, and AC) were compared with moderate atherogenic risk (AIP < 0.24) in RA patients. While a significant decrease was recorded in the HDL-C and BMI levels, it had significantly high atherogenic risk (AIP > 0.24) compared with moderate atherogenic risk (AIP < 0.24) in RA patients. The ROC results analysis showed that the top 5 highly sensitive predictors for RA, e.g., CRI-I, AC, AIP, CRI-II followed by IL-6, have a relatively good sensitivity and specificities for predictors for RA. Conclusion: Increase in interleukin-6 may indicate the activity and severity of the disease. This biomarker could be helpful for early disease detection. The results showed a higher IL-6 in RA patients as well as increased dyslipidemia and atherogenicity in RA patients. Elevation of serum IL-6 and atherogenic indices are the best predictors for RA patients with a higher risk of atherosclerosis than other biomarkers. There is an important correlation between atherogenic indices parameters and the immunological biomarkers IL-6 indicating a significant role of the inflammation in the incidence of atherogenic indices in RA. 
Publication Details
Page(s) 699-705
Published Journal: Anaesthesia, Pain and Intensive Care, Volume: 28, Issue: 4, Year: 2024

Request the full text from PASTIC

Keywords
Rheumatoid arthritis, interleukin-6, Atherogenic Indices.
References
Jafat SM,Obaid RF,Hamzah AA . .Evaluation prognostic value of serum levels of soluble programmed death protein 1 (SPD-1) in patients with rheumatoid arthritis. Biochem Cell Arch., : .
Dessie G. .2022 .Association of atherogenic indices with C-reactive protein and risk factors to assess cardiovascular risk in rheumatoid arthritis patient at Tikur Anbessa Specialized Hospital, Addis Ababa. PLoS One, 17(6) : .
.2021 .. , 12 : 680043.
Kadhim JR,Jabbar KD,Alosami MM,Shareef L .2022 .Medicationrelated burden among Iraqi patients with rheumatoid arthritis: An observational study. F1000Res, 10 : 1047.
Deshmukh R. . .Rheumatoid arthritis: pathophysiology, current therapeutic strategies and recent advances in targeted drug 6. , : .
.2023 .delivery system. Mater Today Commun, 10 : 105877.
Halacoglu J,Shea LA .2020 .Cardiovascular risk assessment and therapeutic implications in rheumatoid arthritis. Int J Clin Rheumatol, 13 : 878-90.
.2021 .. , 33(16) : e2100098.
Kragstrup TW,Andersen T,Heftdal LD,Hvid M,Gerwien J,Sivakumar P .2018 .The IL-20 cytokine family in rheumatoid arthritis and spondyloarthritis. Front Immunol, 9 : 2226.
.2018 .. , : .
Almeida-Santiago C,Quevedo-Abeledo JC,HernándezHernández MV,de Vera-González A,González-Delgado A,González-Gay MÁ . .Disease activity is more associated with IL-1 than with IL-6 in patients with rheumatoid arthritis. Life., : .
.2022 .. , 13(1) : 82.
Strand V,Boklage SH,Kimura T,Joly F,Boyapati A,Msihid J .2020 .High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in healthrelated quality of life for sarilumab compared with adalimumab. Arthritis Res Ther, 22 : 1-9.
Nada H,Sivaraman A,Lu Q,Min K,Kim S,Goo JI .2023 .Perspective for discovery of small molecule IL-6 inhibitors through study of structure-activity relationships and molecular docking. J Med Chem, 66(7) : 4417-33.
Ogata A,Kato Y,Higa S,Yoshizaki K. .2018 .IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod Rheumatol, 29(2) : 258-67.
Ibrahim RA,Al-Tae F. Interleukin RA .2021 .-6 serum level and single nucleotide gene-174 G/C promoter polymorphism in patients with rheumatoid arthritis/Iraq. , 43(2) : 164-75.
Hirano T,Yasukawa K,Harada H,Taga T,Watanabe Y,Matsuda T .1986 .Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature, 324(6092) : 73-6.
Jarlborg M,Gabay C .2021 .Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints. Cytokine, 149 : 155742.
Abbasifard M,Khorramdelazad H. .2020 .The bio-mission of interleukin-6 in the pathogenesis of COVID-19: a brief look at potential therapeutic tactics. Life Sci, 257 : 118097.
Aletaha D,Neogi T,Silman AJ,Funovits J,Felson DT,Bingham CO .2010 .rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum, 62(9) : 2569-81.
Bhattacharya PK,Barman B,Jamil M,Bora K. .2020 .Metabolic syndrome and atherogenic indices in rheumatoid arthritis and their relationship with disease activity: a hospital-based study from Northeast India. -0015, 8(2) : 99-105.
Jang Y,Kim T,Kim BH,Park B .2022 .Association between obesity indexes and thyroid cancer risk in Korean women: nested casecontrol study. Cancers, 14(19) : 4712.
Friedewald WT,Levy RI,Fredrickson DS .1972 .Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 18(6) : 499-502.
Alifu J,Xiang L,Zhang W,Qi P,Chen H,Liu L .2023 .Association between the atherogenic index of plasma and adverse long-term prognosis in patients diagnosed with chronic coronary syndrome. Cardiovasc Diabetol, 22(1) : 255.
Hashizume M,Mihara M. .2011 .The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis, : 765624.
Gaber W,Azkalany GS,Gheita TA,Mohey A,Sabry R. .2012 .Clinical significance of serum interleukin-6 and−174 G/C promoter polymorphism in rheumatoid arthritis patients. Egypt Rheumatol, 11(2) : 107-13.
Koh JH,Yoon SJ,Kim M,Cho S,Lim J,Park Y .2022 .Lipidome profile predictive of disease evolution and activity in rheumatoid arthritis. Exp Mol Med, 54(2) : 143-55.
Shaban SA .2015 .Study the serum IL-6 level between rheumatoid arthritis patients and control. Tikrit J Pure Sci, 10 : 1210-41.
Mohammed AM,Zayni SM,AL-Anee MM,Corial FI,Al-Rubaee AJ .2023 .Diagnostic and predictive values of IL-6 in a group of Iraqi patients with rheumatoid arthritis. J Fac Med Baghdad, 10(2) : .
Boyapati A,Schwartzman S,Msihid J,Choy E,Genovese MC,Burmester GR .2020 .Association of high serum interleukin‐6 levels with severe progression of rheumatoid arthritis and increased treatment response differentiating sarilumab from adalimumab or methotrexate in a post hoc analysis. Arthritis Rheumatol, 72(9) : 1456-66.
Dabeer S,Sharma N,Nagdeote A .2019 .Correlation between CRP and atherogenic index and assessment of cardiovascular disease risk in patients with rheumatic arthritis. Int J Res Rev, 6(12) : .
Cure E,Icli A,Uslu AU,Sakiz D,Cure MC,Baykara RA .2018 .Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis: AIP associate with cIMT in AS. Clin Rheumatol, 37 : 1273-80.
Çelik İE,Öztürk S,Yarlıoğlu M,Barutçu O,Akgün O,Duran M .2023 .The association between atherogenic index of plasma and no-reflow phenomenon in acute coronary syndrome. Anatol J Cardiol, 27(12) : 712.
Cure E,Cure MC .2020 .Comment on “usefulness of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis?”. Adv Rheumatol, 60(1) : 23.
Meena P,Goswami S,Mathur A,Sharma R. .2021 .A study of high sensitive C-reactive protein in rheumatoid arthritis patients. Int J Res Med Sci, 10(1) : 2320-6012.
0

Citations

0

Downloads

69

Views